Review: HISIERRA™ Bags

a word from our sponsors:

advertisement

advertise here

HISIERRA™ bags are one of many recent inventions made possible by the wave of cannabis legalization that’s swept the U.S. in recent years. Designed specifically for use in legal cannabis, HISIERRA™ bags are a sustainable, reusable, renewable and responsible child-resistant packaging solution that will prove useful for anyone in the business of dispensing medical cannabis — from the eco-conscious backyard caregiver to the dispensary owner whose main concern is staying state-compliant.

The bags themselves come in two size categories. The smaller size, called the ‘Daytripper,’ is 9″ x 6″ in dimension; this bag could easily hold up to a quarter of an ounce of flower — or much, much more if you’re willing to squash some nugs. The larger size, a.k.a. the ‘Weekender,’ is 12″ x 9″ and has a 4″ wide gusset base; for the dedicated cannabis consumer, this bag could carry several ounces.

In your hand, the bags feel sleek and sturdy. Aesthetic-wise, the bags are fairly minimalistic, though custom printing options are available on request, according to the company website.

The bags’ locking mechanism is very functional: the zipper slides back and forth easily at the top of the bag, but to access the contents inside you must push the zipper’s tab down into the bag’s seal. Under the Consumer Product Safety Commission Protocol and Standards, HISIERRA™ bags are certified “Child Resistant” under protocol 16 CFR 1700.20 and the Child Safety Standard ASTM D3475 and fully comply with the Poison Prevention Act of 1970. Each pouch is also food-safe verified.

To determine how well the bags can contain strong odors (an important factor for patients who must carry their cannabis with them throughout daily life), our testing team filled an HISIERRA™ bag with the skunkiest product we could find and placed it inside of a personal backpack. We couldn’t detect any odor leakage in the backpack after more than an hour of storage.

“It’s a dream come true for me, to be able to bring something that’s both earth-friendly and responsible packaging,” said HISIERRA™ founder and owner Mike Greenfield, a career packaging entrepreneur based out of southern California. “I’m able to combine two of my passions: that of the cannabis market and helping out as I can; and packaging — I’ve been in packaging my whole career.”

Each HISIERRA bag is constructed using bio-based resins largely extracted from non-GMO sugar cane. “The science behind it is it’s all about carbon,” Greenfield explains. “Instead of using fossil fuels such as crude oil or natural gas, we’re using plant-based biomaterials, and harvesting the carbon from them, changing it into a plastic material.”

HISIERRA™ goes beyond bio-based resins and eco-friendly material sourcing, however, because the entire HISIERRA™ production line is powered using 100% renewable, wind-sourced electricity. The factory is LEED certified Silver. “The air coming out of our factory is cleaner than the air coming in,” Greenfield jokes, but his emphasis on sustainable, renewable and Earth-friendly business practices is very real.

After brainstorming the new packaging technology concept just over two years ago, Greenfield sought help from family members to bring the idea to market — the company logo itself, three mountain peaks, is symbolic for Greenfield, his brother, and his father. “It’s a great opportunity for me to give back. It’s an opportunity for me to give back to my dad and my brother,” said Greenfield. “We’re a small family business, we’re not like one of the big monster companies out there. We’re building it out of the idea of providing a service to our customers.”

HISIERRA™ bags are available in dispensary boxes, which contain 60 bags each, or in a master case, which contains 7 dispensary boxes (or the magic number of 420 individual bags). The company is currently working to create smaller bag options to better serve the concentrates and edibles side of the industry.

You can learn more about HISIERRA™ bags at www.hisierrabags.com or reach out to Mike Greenfield directly at mike@hisierrabags.com.

We love seeing cannabis entrepreneurs put their ingenuity to work to come up with products that set a good example for the industry as a whole, and we’re excited to see what HISIERRA™ does next!

End


Portlanders to Vote on 3% Cannabis Tax Increase

a word from our sponsors:

advertisement

advertise here

Following unanimous decision by the Portland City Council yesterday, city voters will decide this November whether or not to embrace a 3% tax hike on recreational cannabis products, KOIN 6 News reports.

There is a 25% statewide sales tax currently in effect, but that will drop to 17% beginning January 1. After that point, local municipalities across Oregon will have the option of adding a 3% local tax for up to a 20% total tax rate. This November’s ballot measure, if successful, would earmark the money for the city and keep it from entering the general fund.

The move was proposed by Commissioner Amanda Fritz, who said it could raise up to $3 million each year. According to Fritz, the extra tax money would go towards drug and alcohol treatment, public safety, and supporting small Portland businesses.

“There’ll be a robust conversation at council about, are these the right items to dedicate it to? There’s been some suggestions to not dedicate it at all or to put it to something that’s not related to marijuana use, and I think the taxes work best when there’s a clear nexus between the people who pay and the people who benefit and to make sure that that’s fair,” said Fritz.

Oregon does not tax the sales of medical cannabis.

End


New York Gov. Doesn’t Know His State’s MMJ Law is Broken

a word from our sponsors:

advertisement

advertise here

Since its launch in January, the New York medical marijuana program has faced heavy criticism from patient and industry advocates for being too limited. However, in a surprising display of ignorance, New York Gov. Andrew Cuomo told reporters on Wednesday that he was unaware of any concerns over the state’s restricted and controversial medical cannabis program, The Journal News reports.

“I haven’t heard issues that people can’t find access,” Cuomo told reporters in Buffalo. “You don’t have one on every corner because you don’t have that kind of demand. But if you need the drug, you can get the drug.”

A recent survey of New York’s medical marijuana patients and caregivers by the Drug Policy Alliance unearthed serious flaws in the program. In their scathing report, the DPA found the program was plagued by unaffordable medicine and “overall inaccessibility.” Among the top concerns are an ongoing dearth of doctors who are qualified to recommend cannabis to patients, and a lack of information for patients who are seeking marijuana-friendly doctors.

“This should be something that [Gov. Cuomo] is aware of,” said Sen. Diane Savino (D), who has sponsored many of the state’s past marijuana measures. “Now that I know he isn’t aware of it, I’m going to make sure he knows.”

Meanwhile, New York Assemblyman Richard Gottfried (D) and other advocates worked up to the deadline in an effort to reform the program on behalf of struggling patients, but the session ended last week without any legislative action taken towards fixing the program.

End


Congress Neglects MMJ Reforms for Veterans

a word from our sponsors:

advertisement

advertise here

Congressional leaders have blocked medical marijuana reform efforts from both the House and Senate that would have opened the door for Veterans Affairs doctors to recommend medical cannabis to veterans in states where it has been legalized, Marijuana.com‘s Tom Angell reports.

In strong bipartisan votes last month, the legislatures each approved measures to the 2017 Military Construction and Veterans Affairs bill that would have blocked the VA from using funds to enforce policies preventing its doctors from recommending medical marijuana to their patients.

It had appeared that, with bipartisan approval from both chambers of the Congress, the protections would be secure for the bill’s final version. However, new bills are not complete until the differences between the House and Senate are reconciled into a final version of the bill by a conference committee made up of lawmakers from each chamber. Ultimately, neither set of marijuana protections were included in the conference committee’s final version of the bill.

The spending package was assembled late last night, and at 3:10 a.m. the House of Representatives voted 239-171 for its approval. The bill now returns to the Senate for a final vote before continuing on to President Obama.

It has been shown that medical cannabis could be an effective treatment for individuals suffering from PTSD, a potentially debilitating condition that is commonly faced by combat veterans.

End


Dr. Ethan Russo: Endocannabinoid Nutrition

a word from our sponsors:

advertisement

advertise here

In this week’s podcast episode, Dr. Ethan Russo — one of our earliest and most esteemed guests — returns to the show to discuss his latest article, “Beyond Cannabis: Plants and the Endocannabinoid System.”

Dr. Russo is a neurologist and psychopharmacology researcher, and is the former Senior Medical Advisor for GW Pharmaceuticals. He worked as a clinical neurologist in Missoula, Montana for 20 years, where much of his practice focused on the treatment of chronic pain. Today, Dr. Russo is one of the world’s leading researchers in the field of cannabis terpenes and the endocannabinoid system. He has authored several books about cannabis, cannabinoids, pharmacology, and rare botanicals, and he has published over 30 articles covering neurology, pain management, cannabis, and ethno-botany.

Listen along, or read the transcript below, as Dr. Russo and Ganjapreneur podcast host Shango Los discuss how various foods — including black pepper, kava, the common carrot, and more — can actually help balance the cannabinoid levels in your body.

Subscribe to the Ganjapreneur podcast on iTunes, Stitcher, SoundCloud or Google Play.


Listen to the podcast:


Read the transcript:

Shango Los:  Hi there, and welcome to the Ganjapreneur.com Podcast. I am your host, Shango Los. The Ganjapreneur.com Podcast gives us an opportunity to speak directly to entrepreneurs, cannabis growers, product developers and cannabis medicine researchers all focused on making the most of cannabis normalization. As your host, I do my best to bring you original cannabis industry ideas that will ignite your own entrepreneurial spark, and give you actionable information to improve your own business strategy and improve your health and the health of cannabis patients everywhere.

Today, my guest is Dr. Ethan Russo. Ethan Russo is a neurologist, psychopharmacology researcher and former Senior Medical Advisor to GW Pharmaceuticals. He served as study physician to GW for three phase three clinical of Sativex. He graduated from the University of Pennsylvania and the University of Massachusetts Medical School before residencies in pediatrics in Phoenix, Arizona and in child and adult neurology at the University of Washington in Seattle. He was a clinical neurologist in Missoula, Montana for 20 years and a practice with a strong chronic pain component. In 1995 he pursued a three month sabbatical doing ethno-botanical research with indigenous peoples in Peru. He is currently past President of the International Cannabinoid Research Society and is former Chairman of the International Association of Cannabinoid Medicines.

He has authored several books on cannabis, cannabinoids, pharmacology, and rare botanicals and has also published over 30 articles in neurology, pain management, cannabis, and ethno-botany. You can see his full lists of books and credits at the Phytecs website where he is presently Medical Director. To those of you who study his work and seek out his mentorship, he is the godfather of cannabis terpene research as well as a leader in research and popularization of the endocannabinoid system. Welcome back to the show, Ethan.

Dr. Ethan Russo: Well, thank you, it’s great to be back.

Shango Los: For those of you who are unfamiliar with the endocannabinoid system, you may want to hit pause and go back and listen to podcast episode number three where we speak with Dr. Russo about the endocannabinoid deficiency and he talks a lot about the ECS itself. Also, you might want to check out our recent episode with Dr. Greg Gerdeman on the popularization of the endocannabinoid system in human culture.

Today, we’re here to talk about Dr. Russo’s new article recently published in Trends in Pharmaceutical Science entitled “Beyond Cannabis: Plants and the Endocannabinoid System.” Ethan, with all of that, let’s start with a really solid basis for our discussion. For the folks who are not familiar with endocannabinoid system, yet, will you just give us a brief summary to kind of get them on the same page.

Dr. Ethan Russo: Sure, I’d be happy to. The endocannabinoid system, as one can tell from the name, was named after cannabis. This has to do with the fact that the main psychoactive component of cannabis, tetrahydrocannabinol or THC affects the system. One might first wonder, how long it would have taken to discover this system if cannabis were not around. In any event, for a long time after THC was first characterized in 1964, it was thought that it worked by altering some membranes in the brain, something like the way that alcohol works, but, in fact, it turned out that THC works on a receptor called CB1 — that’s for cannabinoid-1. That’s the main psychoactive receptor in the brain.

Some of the effects that THC has in making a person feel high, in reducing pain, affecting nausea and things like that, some of these things are mediated through this CB1 receptor, but, there’s also a CB2 receptor, cannabinoid-2. This one can occur in the brain under conditions of injury or inflammation, but, it’s mainly out in the body where it’s known as an immunomodulatory receptor. It has to do with immune responses, inflammation, and pain. But, those receptors are only one component of what’s called the endocannabinoid system. A few years later, somewhere in the early 90s, it was discovered that there were endogenous cannabinoids. Endogenous means within. It turns out that there are substances in our body that are THC-like, that work on these receptors, CB1 and CB2. The first one that was discovered was called anandamide. That’s taken from the Sanskrit word for bliss and the second is called 2-EG, 2-Arachidonoylglycerol, and both of these will stimulate the cannabinoid receptors.

Then, we have the receptors, we have the endogenous ligands, the chemicals in our bodies that work on the receptors and then the third component of the endocannabinoid system are the enzymes that make these endocannabinoids and break them down. We have this triad then, called the endocannabinoid system.

What does it do? I’ve already mentioned that this is very prominent in the brain. The main activity there is in regulating neurotransmission. I think most of the audience has probably heard of neurotransmitters. These would be things like acetylcholine and norepinephrine. They are the chemical signals in the brain from one nerve cell to another.

What CB1 does in the brain is inhibit the release of neurotransmitters. Let’s say, for example, someone has chronic pain, too much pain. That often goes along with an excess of a neurotransmitter called glutamate, which is stimulatory. If we have THC or anandamide that stimulates CB1 receptor will reduce release of glutamate and often act to reduce the pain. This is just one example.

However, although things started there, in terms of research, it turns out that the endocannabinoid system is a major homeostatic regulator of almost every physiological function in the body. I realize that’s a mouthful. Let’s break it down. Homeostasis is balance of function. What the endocannabinoid system will do in any given area of the body whether it be the brain, hormonal balance, appetite, digestion, is try and bring things back into balance.

In other words, if there’s too much of a neurotransmitter, stimulation of the endocannabinoid system will bring that down back into the range where it should be. In contrast, if there’s too little activity in the system, stimulation of the endocannabinoid system will bring it up back into balance. Almost any function of the body you can name is effected by the endocannabinoid system and it really points out the reason that cannabis is such a versatile medicine for so many conditions that are otherwise very hard to treat with conventional medicines.

Shango Los: I was thinking about that. The way that it regulates the system, it reminds me a lot of this vocabulary word that my acupuncturist used all the time from Chinese medicine that it tonifies the system. If you’ve got an excess, it brings it down to optimum, and if you’ve got too little, it brings it up to optimum, so that essentially, we’re creating, we’re feeding a regulator for our bodies, so if the ECS is healthy, all of these other systems will be healthy as well.

Dr. Ethan Russo: I think that’s quite appropriate and there are many parallels between some of the concepts in traditional Chinese medicine and some of what the endocannabinoid system does, right.

Shango Los: Up until now, your paper talks about how to feed and care the endocannabinoid system with food sources that are non-cannabis. This is a pretty big deal to everybody because up until now, we have been supplementing our endocannabinoid system, which is cannabinoids that are made in the body endogenously, with cannabinoids that we have been getting from cannabis, things like cannabidiol and actually most of the parts of the plant fall into that category, and now the idea that we can go to food sources for it is something that’s got people really excited, because not only is cannabis not easily available everywhere, but also, it certainly has a price point that’s higher than most foods. Your new paper suggests that these can be gotten from food sources. Why don’t we pick one category of cannabinoid and talk about the food sources that it is present in.

Dr. Ethan Russo: OK, we can start off with CB1. I’m sure that many of the listeners are interested in what plants outside of cannabis might have similar effects. Actually, it’s a short list there. If we look at CB1, which is generally of most interest to most people, way back about 2000, I was interested in the possibility of looking at some other plants that affected the CB1 receptor like THC does. We looked at salviadivinorum. It’s sort of a long story, but, we were interested in salvinorin A, which was clearly the most active molecule in that plant. We didn’t get any binding to the CB1 receptor, but interestingly, there was something else in the extract of the plant that seemed to work at that receptor. Along about that time, it was discovered that salvinorin A works on another receptor called the kappa-opioid receptor, and that its activity seemed to derive from that. Subsequently though, some other people looked at salvia again, and there is a relationship there that still is being worked out.

Another one that might be quite odd to people is the common carrot, daucus carota. It actually has a substance in it called falcarinol. This actually seems to have an antagonistic effect on the CB1 receptor.

That’s odd. What would it do? While most CB1 antagonists would reduce hunger and produce some other effects of that sort, but the main importance of this molecule is that if one were handling carrots at the same time that there was histamine around, it’s possible they’d get an allergic reaction. As a doctor, I don’t remember a lot of people getting a rash from carrots, but this is a possibility.

More interesting, I think, is another plant that may stimulate the CB1 receptor. This is piper methysticum, better known as kava. Kava is an interesting substance. This is made from a root of a plant that grows in the South Seas, so it’s common in Polynesia. This is pounded and mixed with water, and it makes a gluey sort of drink that is used as a method of relaxation. Typically, it doesn’t have alcohol, and we had an idea in the past of how this worked on a different set of receptors called gaba. It turns out that a few years back, it was noted that one component of it called yangonin seems to work on the CB1 receptor, and, traditionally, in a traditional dose of kava there may be enough to really affect things. Occasionally, people will say that they feel high in relation to kava, not just relaxed, but, again, this is a relatively recent discovery and needs to be examined more thoroughly.

I’ll mention one other in this category, and this is an unusual one also, this is in liverworts. This is a kind of primitive plant. There are two that have been described, the one from Japan and one from New Zealand. The one from New Zealand is called granular marginata. These particular liverworts have two substances in them that look like cannabinoids. One is called perrottetinene and the other, perrottetinenic acid. This was originally described about 20 years ago, and the author said, “they called them cannabinoids, but, interestingly, at that time, they didn’t test them for activity.” Recently, one of my colleagues, Juerg Gertsch in Switzerland has confirmed that these do act on the CB1 receptor.

Unfortunately, his paper is not yet published, so we can’t get more details. I will say this though, in relation to these plants, there are some … reports that people will find on the internet and they’re odd because some people say that they really got high from smoking this material, and others will say that it didn’t do anything. I’m not sure I can recommend that people experiment with this. It’s not necessarily healthy to try and smoke liverwort. Hopefully we’ll have more details on that. That’s one category.

Shango Los: Let’s unpack two of those. The salvia is around but hard to get for some folks, but, carrot and kava are both really common. Carrot you can just buy at any grocery store, and the kava kava you can get at most herbalists. I’ve got a tincture of kava right here on my desk. When I take it, it does have a relaxing effect to my human. I feel a certain amount of muscle relaxant and a little less care in the world, but, I don’t get that from eating carrots. How can we think about the right manner to ingest, and how does a normal person know the volume, or, is it just simply, “hey, eat more carrots and make yourself some kava kava tea occasionally, and you’re going in the right direction.” How can this help a common person to help their ECS using these?

Dr. Ethan Russo: Right, well, let’s go to the carrot first of all. I would remind listeners that this is actually antagonistic of the CB1 receptor, so, no one is going to get high from carrots. Similarly, it’s really unclear whether this falcarinol is active orally. We don’t know if it gets into the brain. I’ve never heard of anyone eating a carrot and having it reduce their hunger. Additionally, carrots are pretty high on the glycemic index. They have a lot of sugar in them the way they’ve been bred in modern times. I’m not sure it’s a diet food either. Certainly, the person that’s looking for legal highs shouldn’t go in that direction.

With a kava, what is a normal dose? With a tincture, I think people would just go with the directions on the bottle. If they’re making it themselves from the root, it probably shouldn’t be too much. The stuff is pretty nasty to drink, which is one reason that it’s better in capsules or as a tincture, but again, I have it on good authority from Alessia Ligresti, the author of the original article, that she does think that most strains of the kava do have a significant amount of yangonin in them. If someone suffers from anxiety or just needed it periodically, like, to take a test or go to court, I think that kava is usually a good, safe anti-anxiety agent. There were concerns about it in the past in relation to possible liver damage, but that was related to one particular preparation that’s not commercially available now. This has a long history of safe use in Polynesia.

Shango Los: I think the most important part I got out of that is just because we’re talking about food sources doesn’t necessarily mean you just eat this stuff and your ECS is going to be in better shape. It’s more about these are suggestions of places that you could continue your personal research to find out which of these might be better for you and determine the right amount for you to take. What we’re not saying is “this is just plug and play.” What we are saying is that these are some doors that are being opened by your research that shows that there are components in these plants that we need to figure out how best to introduce to our body. Does that sound like a good summary?

Dr. Ethan Russo: Yeah, that’s a great point. Again it’s, to me, maybe not the best place to start with CB1, but, it usually is the most interesting to people, being the psychoactive receptor. In fact, we may do better in this regard looking at some of the other plants for their effects, so, maybe we can transition into those.

Shango Los: Why don’t we go ahead and take our first break, because I’m excited to talk about CBG from food, and I think that’s going to take us a little bit. Let’s take a short commercial break and be right back. You are listening to the Ganjapreneur Podcast.

Marketing and brand agencies can be really unhelpful sometimes. You pay them and have meetings, but there doesn’t always seem to be real value created. Sure, they may make you a logo or a website, and you talk about the image your company wants to project, but that is not always reflected in the bottom line in the form of actual revenue. For a lot of start-ups, everything has got to feed the bottom line, just so they can survive.

That’s what Blunt Branding does. They feed your bottom line. Blunt is very different from other agencies because their principals, Kiersten Nelson and Anthony Garcia are experts in psychological marketing. For example, they don’t just write copy for your website, they write copy that includes hooks and triggers for every Myers-Briggs personality type. Most copywriters tend to write only for people who think like them. Blunt Branding does better than that. They reach all your potential customers. In fact, if there’s a certain kind of customer that you don’t want, say, argumentative folks, Blunt will write you copy that attracts everyone else, but will tend to repel the kind of customer that gives you grief. I’m not kidding. This strategy is used by their attorney clients all the time. Your brand is much more than a logo, you see, most customers wait for some company to wow them with something more than they came shopping for, especially when there are so many options, right. They’re looking for a brand to anticipate their questions or solve their problems or just make them feel seen, heard and valued.

I know that can sound corny, but we all know that we buy from the companies we feel most engaged with, and Blunt Branding will get them climbing over your competitors to get to you. If you cannot risk business failure, you should be working with a marketing team who understands that their goal is not just to make you pretty, but to directly increase your sales success, too. Go to BluntBranding.com to find out more.

Welcome back. You are listening to the Ganjapreneur.com Podcast. I’m your host Shango Los. Our guest this week is neurologist and cannabis researcher, Dr. Ethan Russo.

Before the break, we were talking about different food sources that could work with the CB1 receptor to help manage your endocannabinoid system. We’re ready to move on from there to talk about CBG, cannabigerol, and, Ethan, I understand that you have found food sources for that, or, maybe just one. Your paper talks about a flowering plant in southern Africa. Is that something that we can even get in the United States?

Dr. Ethan Russo: Oh boy, that’s tough. This is an odd one. Again, traditionally, it’s been thought that cannabis was the only source of cannabinoids, but, it’s turning out not to be true and that was the reason for writing this article. Actually, more than 30 years ago, there was an obscure article written in German about finding cannabigerol, one of the so called minor cannabinoids of cannabis, in this flower from southern Africa. It’s called helichrysum umbraculigerum, and, although it is, I understand, a common roadside plant in South Africa, they’ve got very strict laws about intellectual property in South Africa, and it’s not something that you’ll find commercially. I’m happy to say that we have legally obtained a supply of this and aim to investigate it further.

What the original article said was that two cannabinoids, cannabigerol, which is the decarboxylated form, it’s lost its CO2 and its precursor, the cannabigerolic acid, the acid cannabinoid were found in this flowering plant. Unfortunately, the original article never stated the concentration. The issue is, is there a significant amount of these chemicals in this plant, and could it possibly be a non-cannabis source for cannabigerol? That’s the question. Unfortunately, we don’t have the answer yet. We’ve just procured the plant and we’ll be doing the bio-chemical assays to try and answer that question.

It raises a bunch of other issues. In most countries, this is not a big deal. Cannabigerol is not a scheduled compound, meaning it’s not forbidden, but, in the U.S. it would be considered illegal. Now, all of a sudden, you may have a situation of this attractive flower could be illegal to grow in the U.S. We just don’t know what will happen with that. It’s just another example of quirks in the law. Unfortunately, in my opinion, these laws are not subject to the teachings of science. In this instance, it’s guilt by association. Cannabigerol happens to be produced by the cannabis plant, and I’m not sure that legislators necessarily care whether it appears in another plant that happens to have a pretty flower and have other purposes.

Shango Los: It’s like getting blamed for something that your cousin did.

Dr. Ethan Russo: Yeah, you bet.

Shango Los: Since we’re not sure if we can even get our hands on it, let’s move right along to anti-inflammatories. You’ve got a nice list of foods where we can get some caryophyllene. What are those foods and whatt’s the best way to go about enjoying them?

Dr. Ethan Russo: First, there’s just a little background. Caryophyllene is what’s called a sesquiterpenoid. That means it’s a 15 carbon terpenoid. It’s got sort of a balsamic aroma. People may think they’re unfamiliar with this, but I bet they are, actually, because it is one of the components of black pepper and it’s responsible for some of its taste and its effects, but, caryophyllene appears in a bunch of different plants and it’s not just black pepper, but, many others.

Shango Los: A couple others that you mentioned in your paper are chili peppers, and ginger, and euphorbia, which I was surprised. It’s probably a different euphorbia than is growing in my yard.

Dr. Ethan Russo: We need to back up a little bit. Caryophyllene beyond cannabis and the black pepper is going to be in cloves, it’s going to be in hops, and melissa, lemon balm. The importance of this is, about 10 years ago, again, Juerg Gertsch in Switzerland discovered that caryophyllene is a CB2 agonist. To reiterate, CB2 is the non-psychoactive receptor. That’s important in treating inflammation and pain. Caryophyllene, which happens to be in cannabis also is at once a terpenoid and a cannabinoid in its own right, and it was well established long before we knew it had this effect on CB2 that caryophyllene is a very effective agent in treating inflammation and pain. The copaiba balsam, copaiba is a tree in South America and its sap, which has a lot of caryophyllene in it has been used traditionally by indigenous groups and other people in South America to treat wounds, arthritis, and things of this sort. Certainly, this is one instance, where if you had steak au poivre, you have a good intake of black pepper, you may be positively modulating your endocannabinoid system. If anybody was thinking that there aren’t accessible agents that could help tune things up with respect to the ECS, here is a good example.

Shango Los: Is black pepper, in this case, this is one of the cases where it is appropriate for us to simply eat it, where we don’t necessarily have to make a tea or a tincture or something like that to make it bio-available, we can simply just eat it and our body will process it, and it will support the ECS.

Dr. Ethan Russo: I believe that’s true. That doesn’t mean that everybody has to have a huge amount, but, I’m one of those people that tends to put black pepper on everything, and I did that long before I knew that it might be helping me.

Shango Los: Right on then … go ahead.

Dr. Ethan Russo: Black pepper is really interesting, because that’s not the only effect it has on the ECS. It also effects another related system that’s called the TrpV1, that’s the transient receptor potential vanilloid 1. This is also considered part of the endocannabinoid system. It’s going to be most familiar to people from the other kind of pepper, red pepper, capsaicin, the chili peppers. Capsaicin is a TrpV1 agonist, so it’s famous or infamous for its burning sensation. What’s interesting about the TrpV1 receptor is although some of the agents that stimulate it, like capsaicin, burn. That burn goes away after a while because the receptor becomes desensitized. This can be used to advantage in treating pain. People may have seen on TV, ads for ointments that have capsaicin in them and they’re used to treat pain, particularly nerve based pain. For example, if someone has diabetic neuropathy, a burning pain in the extremities, if they apply this kind of ointment with capsaicin in it, say, three times a day over a period of time, it can actually reduce the pain. It’s very cumbersome to do, but it can be effective.

Interestingly, there are other things that do this. Ginger has TrpV1 agonist in it, and again, black pepper. This is a situation, we’re not sure how much of this gets absorbed, and whether just eating foods that are rich in TrpV1 agonists will help with, say, arthritic pain, but, we do know, and this is odd, that people who have inflammation of the gut, say, with irritable bowel, sometimes will benefit from regular use of spicy food, particular regular use of chili peppers. People are well aware that in certain cuisines, say, India, southeast Asia, that chilies are in almost everything, and this may be one of the reasons.

Shango Los: I’m starting to get the idea that this research is pretty bleeding edge. We’re talking about a lot of these different examples, but how to get it into our body, and in what amounts, and what the exact effect seems to be open to discussion and additional research. It sounds like not only do we want to look more into these examples of food sources, but we also don’t entirely know how best to get them into our endocannabinoid system, so, we’re kind of at the beginning of this new family of research.

Dr. Ethan Russo: That’s absolutely true. I’m very excited about this. There is work that’s yet to be done. Like anything, particularly dietary, you would not want to make it your sole focus by any means, but, certainly these foods, your body is going to rebel if there’s too much, so that would be one signal. There actually are other areas where we can give some guidelines on how to use food to optimize the ECS. We haven’t heard what may be the best part yet.

Shango Los: Meaning that research hasn’t been done yet, or that we just haven’t gotten to that point in your paper yet?

Dr. Ethan Russo: The latter. I think we’ve got another chapter coming up here that might be more helpful on a practical level for people.

Shango Los: Right on; I follow what you’re saying. One of the things that struck me, in your paper, you’re talking about additional CB2 agents that are available to us, and there, right at the top is echinacea, and in one way it surprised me to see echinacea there because we take echinacea to get rid of or to postpone our colds all the time, but, I never really considered it something that was going to be acting upon the endocannabinoid system. I’ve got a two-part question. To what degree or what is the mechanism for echinacea to act upon our ECS, and, you know, we’ve been using this plant for thousands of years, and how do we understand that humans came across using these plants? Was it simply by trial and error?

Dr. Ethan Russo: That’s interesting. First of all, for people who aren’t familiar with it, echinacea, usually it’s the root that’s used, and this is a Native American plant. How Native Americans discovered this is hard to say. It could have been empirical, you know, that they were looking for food and someone tried this. It has an unusual effect, it has a sort of local anesthetic effect in the throat, and somebody may have tried to eat this in a moment of hunger, and discovered that it had this local anesthetic effect when they had a cold, and one thing leads to another. I wouldn’t rule out that some of this could have been learned by divination, although, less common in North America, certainly in South America, many useful medicinal plants are discovered by use of ayahuasca, the vine of the soul, and what plant do I need to take care of this ailment. In this instance, I think we may never know how people happened along this knowledge.

Shango Los: I have to follow up on that one. To be discovered via divination, using ayahuasca, I think that what you’re pointing at is when the person would intake the ayahuasca, this would open up their energy centers to be able to get information from the surrounding plants, and somehow the plants would let the person know that they should look towards this plant. Is that what you’re suggesting?

Dr. Ethan Russo: Yeah, it is, and I realize…

Shango Los: That’s great.

Dr. Ethan Russo: This may go far beyond the credence of many of our listeners, but I’ve seen it happen in South America, and I wouldn’t rule out that the same happened in North America among the indigenous peoples. We modern humans have largely lost this capability, but, either through happenstance or experimentation, it was discovered by people that echinacea root had useful properties in reducing not just the pain of a sore throat, but also in shortening the duration of this kind of illness. As it turns out, though, this is an agent that works on CB2, and so it may have a lot more applicability medicinally than just trying to shorten the duration of your cold. CB2 agents, again, seem to be very useful in reducing inflammation and also reduce fibrosis. Fibrosis is scar tissue.

Let’s give one example. We have an epidemic of hepatitis C that leads to scarring, fibrosis of the liver, and a CB2 agent taken regularly could help prevent that. This is a real possibility. Additionally, these CB2 agents may be useful in autoimmune diseases, but we don’t know yet whether that’s the case. Again, this is one of those areas that although it’s tantalizing, we’ve got at this point, many more questions than answers.

Shango Los: You’re right, it is tantalizing. Before we go to the commercial break, I want to follow up with one more question about the divination aspect of it. In the introduction, I mentioned that you did a sabbatical in Peru with the indigenous people studying their healing botany, and I’m sure that was really interesting. In looking at the list of books that you had written, I wish I had it in front of me, but I believe that you wrote a book about your experience in Peru. If I go and pick up that book, do you write about divination in that book? I’d love to hear your thoughts on that, which today is not the place, but, would those thoughts be in that book?

Dr. Ethan Russo: Yeah, the book I wrote called “The Last Sorcerer, Echoes of the Rain Forest,” is actually a work of fiction, and yes, it does discuss divination, but that was a fictional account.

Shango Los: Right on, very good. We’re going to take another short break and then we’re going to talk some more about this, about how to support your endocannabinoid system with common foods. We’ll be right back. You are listening to the Ganjapreneur.com podcast.

The Ganjapreneur Podcast is listened to by tens of thousands of cannabis entrepreneurs and enthusiasts every single week. These folks are most likely your target customers, and we’d like to introduce you to each other. Our down to earth and information rich commercial breaks can deliver your message to the cannabis business community and others who just find relief in getting high. If you want to reach out and connect with our audience in the most personal way that we can offer, go ahead and drop us an email at grow@ganjapreneur.com, and we can talk about you becoming a commercial sponsor of the podcast. Thanks for listening and being a part of the Ganjapreneur family. Now back to the show.

Welcome back. You are listening to the Ganjapreneur.com podcast. I am your host, Shango Los. Our guest this week is neurologist and cannabis researcher, Dr. Ethan Russo. Ethan, we were talking about some of the things that are more common that folks could eat that could help their endocannabinoid system, and one of the things that you mentioned in your paper that I actually have quite often is galangal root. In the same category is apples and blackberries, and they all contain the flavanoid, camphorol, which can be taken to boost serum AEA levels. I’ve got to admit, I don’t actually really know what AEA levels are and why that’s a benefit. Why don’t you break that out a little bit for us.

Dr. Ethan Russo: Sure, so, AEA is just short for anandamide. The full name of anandamide is arachidonyl ethanolamide. Again, it’s that first discovered endogenous cannabinoid that works on the CB1 and CB2 receptors. AEA levels in the body are regulated by an enzyme that breaks it down called FAAH, fatty acid amino hydrolase. There are actually substances available in nature that inhibit FAAH. FAAH inhibitors, if they’re around will boost anandamide by preventing its breakdown. It would sort of be analogous to what an SSRI anti-depressant does with serotonin, say, Prozac for example, but in this instance, working to boost anandamide levels. The substance you mentioned, camphorol is in galangal root, which is used in, say, Indonesian cooking, but, more commonly, particularly here in the northwest would be apples and blackberries, we’ve got tons of them. There are small amounts of camphorol in those, and it may be that, if you’ve got a good intake of that, your apple pie or blackberry pie, may inhibit the breakdown of anandamide and give you a boost that way, it’s really possible.

Shango Los: Anandamide is pretty popular. Are there any other foods that we should be aware of that’s got anandamide in it?

Dr. Ethan Russo: Yeah, the problem is, yes, there is. The most obvious example is a recent discovery that truffles, specifically the black truffle, tuber melanosporum actually contains anandamide. Anandamide normally isn’t present in plants, but then I have to remind the listeners that fungi are no longer considered plants. They’re actually more like animals than plants, and they’re in a group of their own at this point, but, the way that the truffles use the anandamide is a little bit different. They develop more anandamide as they get darker in color. It has to do with the production of melanin, the dark pigment that makes the truffles black or produce darker skin as in tanning or in darker races. This is interesting. The problem is that it’s not enough to eat anandamide. Unfortunately, for our purposes, even if you had access to a bunch of truffles, the anandamide in them would be broken down in your digestive track before you had a chance to get it absorbed out into the body. It may be a better strategy to use the galangal or the apples and blackberries to inhibit the breakdown of anandamide and increase its amount in the body that way.

Shango Los: That makes a lot of sense. Chances are, the black truffle taro chips that I have in my kitchen are probably not going to be the best source, either.

Dr. Ethan Russo: No, but, if you enjoy them, have at it.

Shango Los: One of the things that jumped out at me in the paper was your pointing out that chocolate does not have cannabinoids, as is commonly thought, but there actually are other benefits. What are those other benefits?

Dr. Ethan Russo: Right, so, just to reiterate, there are no endocannabinoids in chocolate, however, it may have the same benefit, it has other health benefits, particularly if it’s not sugar laden, but, it contains a couple of ingredients called ethyleneamines that are FAAH inhibitors. When someone eats chocolate regularly, they may be boosting their anandamide level that way, so it’s an indirect effect rather than a direct one.

Shango Los: That makes sense. Let’s finish up with prebiotics and probiotics. We hear a lot about probiotics in the media, as well as in growing our gardens, but in this application, it’s different. What are the prebiotics and probiotics that are coming from food sources that we should be aware of?

Dr. Ethan Russo: First, let’s define some terms. Probiotics, probably more familiar to people, but won’t be familiar to everyone. Probiotics are actually bacteria that are native to our gut. These are beneficial bacteria. If you didn’t have any, chances are you couldn’t survive, but, they actually have a key role in digestion and prevention of disease. These are going to be most familiar to people in the form of yogurt, so, lactobacilli, also bifido-bacteria. We have this unfortunate concept in our society that bacteria are a bad thing, we couldn’t survive without them, and like anything else, there are good bacteria and bad bacteria. In this particular instance, the good bacteria help prevent diseases caused by the bad bacteria. You hear a lot about e. Coli epidemics, one of the ways to stem that kind of affliction is by having a healthy gut with the right bacteria. The first thing to understand is we can supplement this by having yogurt in our diet, or, people that don’t use dairy products could get some of the same effects with kefir or other fermented foods, particularly things like sauerkraut, or lacto-fermented vegetables. They can be made without any dairy products, just through natural fermentation as lactobacilli are in nature, naturally. Sour dough would have these as well, and these are just absolutely key to health.

The other side of the coin is prebiotics. Prebiotics are vegetables that feed the probiotics, the good bacteria. Some of these are going to be quite familiar, and others not so much. The familiar ones would be the LEACI, these are members of the onion family: your common onion, garlic, leeks. This is another one of those situations, I put onions in almost everything, and it’s a very healthy food in terms of feeding the good gut bacteria, but, there are many others that also have this effect, particularly things that contain a chemical called inulin, or other fructooligosaccharides, that’s a mouthful, so let’s just call them FOS for short. These would include things like acacia senegal, gum arabic, and some less familiar foods, chicory root, Jerusalem artichokes or sunchokes, and things like dandelion greens and burdock root. Burdock is quite popular in the far east, probably much less familiar to folks in the west. Any of these foods, again, are just dynamite in terms of being feed-stock for the beneficial bacteria. Although you can’t always get dandelion grains at the market, a lot of these things are available in capsule form as supplements. The acacia fiber, which is particularly good for people with gut problems is available as a commercial product online and can do wonders for people with, say, irritable bowel syndrome.

Shango Los: One of the things I like about the prebiotics and probiotics section is we have finally hit on something that people can really apply themselves to get their hands on. It sounds like a lot of the prebiotics are plants that we can wild craft, and many of the probiotics, heck, I’ve got a crock going, making some sauerkraut right now that is dairy free, so, look, I’m making a probiotic that is helpful for my endocannabinoid system. I think it’s really helpful to be able to focus in on something that we can actually do that’s tangible to help ourselves. That kind of leads me to where I want to summarize here as we come to the end of the show. It sounds like … We’ve talked about a lot of different plants today, and we know varying amounts about them. It sounds like research is taking place and it’s very promising, and it sounds like it would be a great field for people interested in the endocannabinoid research to go into and that it’s also a good field for just the simple citizen scientist to get into the research and learn more, and tell your friends and certainly tell patients.

To cap us off for the day, in retrospect, looking at all of these different options, what would you just ell a friend over dinner would be three or four foods that they could find relatively easily that would help them out and be a great place to start. Just, like, add these to your diet, and you’re going to be better than without them?

Dr. Ethan Russo: Yeah, it’s great to have the opportunity for a change, give people practical advice in this regard, but I would certainly encourage people to incorporate sauerkraut in their diet, other lacto-fermented foods like naturally fermented pickles, kimchi is excellent in this regard, in the Korean section of the supermarket. Again, the LEACI, the onions, garlic, leeks, and particularly people with gut problems, the acacia senegal, gum arabic, fiber is excellent in helping to treat that kind of problem.

Shango Los: Fantastic, now everybody has a solid to-do list. Ethan, I know that the show has gone longer than I’ve asked for your time today, so I’m going to wrap up now. Thank you so much for being on the show, and introducing us to this new area of research that we can all get excited about and start learning more for ourselves.

Dr. Ethan Russo: Thank you for the opportunity.

Shango Los: Dr. Ethan Russo is an internationally beloved neurologist and cannabis researcher, currently Medical Director at PhytECS. To find out more about Dr. Russo, you can go to Phytecs.com, that’s P-H-Y-T-E-C-S, or simply search his name, Russo, R-U-S-S-O, on researchgate.net, and start reading his research. If you want a copy of the article we were talking about today, you can email him directly. It’s still out for sale right now, so we’re not able to post it on the website just yet, but if you want to email him at EthanRusso@comcast.net, he will send it to you personally. Also, remember that Dr. Russo is an active international traveler, so don’t expect an immediate response.

You can find more episodes of the Ganjapreneur.com podcast in the podcast section and also in the Apple iTunes Store. On the Ganjapreneur.com website, you will find the latest cannabis news, product reviews, and cannabis jobs updated daily, along with transcriptions of this podcast. You can also download the Ganjapreneur.com app in the iTunes and Google Play shops. For info on me and where I will be speaking, you can go to ShangoLos.com.

Do you have a company that wants to reach our national audience of cannabis enthusiasts? Email grow@ganjapreneur.com to find out how. Today’s show was produced by Michael Rowe. I am your host, Shango Los.

End


Snoop Dogg Facing Trademark Infringement Lawsuit by Canadian Sports Network

a word from our sponsors:

advertisement

advertise here

Maple Leaf Sports and Entertainment (MLSE), a professional sports network based out of Toronto, Canada, has filed a trademark infringement lawsuit against Leafs By Snoop, a cannabis company that offers a selection of marijuana products hand-picked by the internationally acclaimed rapper/ganjapreneur Snoop Dogg.

MLSE, the parent company for the Toronto Maple Leafs professional hockey team, filed its opposition suit on June 8 and requested time to explain why the Leafs By Snoop logo infringes on the network’s own design.

The logos, pictured above, bear similar design choices but sport obvious differences in color and font selections.

According to Christopher Sprigman, an intellectual properties professor at the New York University School of Law, “The Maple Leafs might say that their brand has been tarnished by confusion over Snoop’s new logo.”

“That’s quaint but a tough argument,” Sprigman told the Turner Sports Network. “I don’t see a lot of overlap between Colorado pot smokers and Maple Leafs fans.”

Neither MLSE spokesman Dave Haggith or Snoop’s attorney Lawrence Apolzon chose to provide statements for TSN’s report.

Snoop Dogg is one among many American celebrities to get involved in the newly-legalized industry. Leafs By Snoop launched last November, and the company currently offers a wide variety of cannabis flowers, edibles and concentrates in dozens of dispensaries throughout Colorado.

Other celebrities, including Willie Nelson and Whoopie Goldberg, have also created personal marijuana brands.

End


First Legal Cannabis Crops Harvested in Uruguay

a word from our sponsors:

advertisement

advertise here

International Cannabis Corp and SIMbiosys harvested the first legal marijuana crops in Uruguay earlier this week, reaping about 300 grams each, which will be sold at licensed pharmacies in the South American nation, according to a report from High Times.

The plants were planted in February in the companies’ facilities in Montevideo under the authority of the Institute for the Regulation and Control of Cannabis. It is estimated that the initial cultivation process, including drying, manicuring and packing, will conclude by August. Uruguayans will then be able to buy up to 40 grams per month at a set price of one euro or $1.20 per gram. In addition to the Montevideo-metropolitan-area pharmacies – which will be closely monitored – 3,000 people have been registered as individual growers and 15 cannabis clubs will be permitted to grow up to 99 plants each.

Under the law, manufacturers cannot brand their strains or products and all advertising is banned. Tourists are also barred from purchasing cannabis at the retail locations. The drug will be sold at the pharmacies in packets of five or 10 grams and the stock will be renewed every 15 days.

The Uruguay Medical Union is also developing a model for cannabis therapies.    

End


Massachusetts Legalization Campaign Submits Excess of Signatures

a word from our sponsors:

advertisement

advertise here

The Campaign to Regulate Marijuana Like Alcohol submitted more than 25,000 signatures to Massachusetts officials on Tuesday, far surpassing the 10,792 required to add a recreational marijuana proposal to November ballots, the Associated Press reports.

Under the plan, people 21-years-old or older would be allowed to possess up to 1 ounce of marijuana for personal use. Retail sales would carry a 3.75 percent excise tax, on top of the current 6.35 percent sales tax.

Jim Borghesani, spokesman for the organization, indicated that the signatures were submitted to officials well before the deadline, clearing one of the hurdles used by regulators to invalidate petitions. Having more than double the required signatures will also help to ensure they can cover any signatures are disqualified for various reasons, such as being ruled ‘stale’ – an issue advocates in Michigan are currently battling.

Republican Gov. Charlie Baker, Democratic Attorney General Maura Healy, and Democratic Boston Mayor Marty Walsh have been outspoken opponents of legalizing marijuana in the state, calling it a “gateway drug” while the state is grappling with an opioid crisis.

A lawsuit that claims voters who signed the petitions were not told the marijuana products may contain “potent” levels of THC has not yet been ruled on by the Supreme Judicial Court.     

End


DEA Announcement Expected Soon, Rumors Fly

a word from our sponsors:

advertisement

advertise here

If you follow cannabis news with any regularity, you likely noticed the controversial headline, “U.S. Gov’t Will Legalize Marijuana on August 1,” published June 18 by a weekly paper out of Santa Monica, California.

The Santa Monica Observer reported on Saturday that an anonymous attorney for the Drug Enforcement Agency (DEA), with inside knowledge of the situation, disclosed plans by the DEA for the rescheduling of cannabis to Schedule II on the Controlled Substances Act, effectively legalizing medical marijuana in all 50 states. The catch is that patients would require a doctor’s prescription and the product would have to be handled by pharmacies, not dispensaries or caregivers — and it could potentially spell utter catastrophe for the legalized industry.

Cannabis is a Schedule I substance in the eyes of the federal government, with “no currently accepted medical use.” Moving marijuana down one step would put it on the same level as oxycodone, morphine, methadone and other opiate prescription drugs. It is widely-accepted among cannabis advocates, however, that the most ideal course of action would be to remove cannabis entirely from the Controlled Substances Act.

The Observer‘s article has been both cited and criticized by other cannabis publications, including a scathing counter piece by The Daily Chronic that argues professional journalism ought to rely on more than just a single source, speaking anonymously.

In April, the DEA said it would announce its decision about whether or not to reschedule cannabis during “the first half of 2016.” Anticipating the announcement, The Denver Post recently published an editorial by Tom Downey — a regulatory attorney for the Colorado law firm Ireland Stapleton Pryor & Pascoe — in which he proposes a plan for the DEA to facilitate the responsible regulation and normalization of cannabis.

With the final days of June ticking away, the Observer‘s piece could be either an actual leak of privileged information or a ploy to generate discussion and readership, playing off the suspense of waiting for an historically dogmatic and myopic agency’s decision about one of the most hyped progressive movements in decades.  In either case, we are expecting a major announcement from the DEA in a matter of days.

Jedidiah Haney, Interim Board Secretary for The Cannabis Alliance, told Ganjapreneur that he had been initially skeptical of the reclassification rumors, but that he didn’t completely rule them out. “Anything is possible,” he said. “The government is playing shadow games.”

According to Haney, a Schedule II reclassification would require an entire re-writing of most legalized states’ marijuana laws, both medical and recreational. When asked whether Schedule II might embolden the federal government into taking action against state-legal marijuana businesses, Haney noted that the government’s current policy of non-enforcement is a result of the Cole Memo, established in 2013, which says the federal government will not take action against state-legal cannabis companies so long as such enterprises are compliant with local regulations.

However: “It’s a memo,” Haney said. “At the end of the day it’s an opinion. That opinion can be fickle and it can be charged to change. But is it worth federally prosecuting all the people that have engaged in the experiment? Probably not.”

Dr. Dominic Corva of the Cannabis and Social Policy Center told Ganjapreneur that he believes the DEA will bring cannabis down to Schedule II, “because that’s a move that’ll be supported by the pharmaceutical … and banking [industries].”

“I just don’t see the DEA being any more progressive than they have to be,” Dr. Corva said. A Schedule II reclassification would remove the federal penalties preventing corporate banks and pharmaceutical companies from entering the cannabis space, and Dr. Corva anticipates that the opportunity to enter the nascent, flourishing market will be seized.

Dr. Corva sees the post-rescheduling marijuana industry as one that will be forced to juggle persisting cultural stigmas about cannabis use against a growing need for a more normalized understanding of the plant itself.

“The work to be done to make cannabis not be perceived as a social threat is extremely incomplete,” he said. “The businesses don’t get that they have to convince the public that this is okay … and they aren’t putting any effort into that.”

For Dr. Corva, whether or not the federal government decides to take action against state-legal enterprises is a less concerning issue:

“The Cole Memo itself, however it will be revised — which I anticipate it will — could loosen things up, but here’s the problem: it’s not just about the feds, it’s about local politics. And it’s about cultural politics. And rescheduling is not going to change anything about either of those — the feds can reschedule, but the states might not. And whatever the states do, their local jurisdictions are going to have to opt in or opt out.”

In any event, we will be watching closely (and anticipate the same from everyone involved in the cannabis industry) for the DEA’s upcoming and undoubtedly game changing announcement.

End


New York Legislature Fails to Pass Any MMJ Related Bills At Session’s End

a word from our sponsors:

advertisement

advertise here

The New York legislature failed to enact any of the proposed fixes to the state’s medical marijuana program before the legislative session ended last week, despite two bills – one allowing nurse practitioners and physician assistants to certify patients and another making the physician list public — passing the Assembly.

Assemblyman Richard Gottfried (D), who sponsored the initial Compassionate Care Act, said the Republican-led state Senate failed to show any willingness to enact the Assembly-approved proposals that would have helped patients struggling to get enrolled in the program, and that the Health Department should “take the steps within its power” to improve the program without legislators having to introduce legislation.

“There are still too few practitioners participating in the program, and patients should not have to try to find information through social media or randomly calling doctors,” he said in an email with Ganjapreneur. “Without action, New York will continue to deny care to tens of thousands of seriously ill patients.”

Two other bills, one to remove the 10 milligram limits and add eligible conditions, and another adding chronic pain not associated with a listed condition, failed to make it to the Assembly floor for a vote.

Last week, the Drug Policy Alliance released a report that found New York’s program is plagued by unaffordable medicine and “overall inaccessibility.” Kate Bell, the legislative analyst in charge of New York for the MPP, said they are “disappointed” at the legislative failures, calling the program “deeply flawed.”

“New York has one of the smallest number of patients per capita because it is so difficult for patients to access their medicine. Expanding the list of providers who can recommend medical marijuana is something that has been effective at expanding access in other states, and chronic pain, which is not included in New York, is one of the most common conditions for which patients use medical marijuana elsewhere,” she said in an email. “Adding chronic pain to the list of qualifying conditions could also have helped reduce New Yorkers’ use of far more dangerous opioid painkillers.”

Julie Netherland, director for the DPA’s Office of Academic Engagement, says that even if these measures had been enacted by the legislature, the program would still be unaffordable for most present and future enrollees.

“More and more patients are basically saying they are going to continue purchasing medicine on the black market because it’s so much cheaper,” she said. “So we had hoped that, with the proposed legislation, [New York] could expand the market and bring the costs down — so that is still a major concern.”

Netherland explained that the low-enrollment, high-cost nature of the program is “challenging” for the five companies approved to cultivate and dispense cannabis in the state, but none have indicated to her that they plan on dropping out of the program.

However, it remains difficult for those producers to open up dispensary sites quickly because they, so far, have probably not seen returns on their initial investments and fees paid to the state.

“[Owners] have to jump through a lot of hoops,” Netherland said. “I think that creates a lot of costs for them.”

Under the law, the Health Department Commissioner has the power to make any of the changes that have been proposed by lawmakers, but have thus far decline to do so, forcing the issues to be hashed out in the legislature.

While the Health Department does not comment on pending legislation, in an email they lauded the 5,066 certified patients, and the more than 600 participating physicians enrolled in the program’s first five months.

“As these numbers continue to grow, our focus … will remain on ensuring that patients whose doctors believe they can benefit from medical marijuana have access to treatment,” the statement read. “We will continue to monitor the program and consider options to make it as effective as possible.”

End


New Health Office in Las Vegas Will Cut Down Wait Times for Medical Cannabis Approval

a word from our sponsors:

advertisement

advertise here

Officials in Nevada have opened a Division of Public and Behavioral Health office in Las Vegas in an effort to cut down on wait times for patients enrolled in the state’s medical marijuana program, according to an Associated Press report.

The new office is the result of a partnership between the state and Nevada Dispensary Association.

Patients will now be able to bring their applications directly to the office and could see their prescriptions filled the same day, removing weeks of waiting by patients who previously had to mail their doctor recommendations to an office in Carson City.

State Sen. Patricia Farley said the new office removes “barriers to simple, efficient access to medical marijuana patient cards.”

“I am impressed at the efforts the Nevada Dispensary Association and the Division have expended toward reaching the common goal of serving Nevada’s patients,” she said in the report.

When Nevada’s first dispensary opened in Starks last July there were 10,000 medical marijuana cards issued by the state. Today there are more than 18,000 people approved to use cannabis therapies in Nevada.

Joe Pollock, deputy administrator for the division, said the new office will streamline the process for obtaining medical cannabis in the state.

“We are pleased to expedite, improve and simplify this process to make the medical use of marijuana more readily accessible for patients,” he said.

End


Will ‘Big Marijuana’ Ruin Everything? Major Brookings Report Says No

a word from our sponsors:

advertisement

advertise here

“Worry about bad marijuana — not Big Marijuana,” reads the headline of a Brookings Institution report released last week. The report was written by John Hudak and Jonathan Rauch, both senior fellows in governance at Brookings.

The possibility of corporate cannabis lobbying has proven to be of concern for lawmakers and activists alike, though Hudak and Rauch take a stand against such alarmism in their latest report. Their report argues that, rather than worrying about a potential corporate marijuana takeover, lawmakers would be better served addressing consumer safety in a freshly legalized cannabis market.

According to the authors, corporatization often leads to more responsible business practices among peers. “The best regulation is the one that doesn’t need to be imposed, because reputational accountability or market pressures solved the problem first,” Hudak and Rauch wrote.

Ultimately, Hudak and Rauch compare the likely future of legal cannabis to that of alcohol — a regulatory model far displaced from the “notorious heyday” of Big Tobacco.

From the authors’ conclusions:

“The marijuana industry will remain a diverse one even as large corporations emerge. The Big Marijuana rubric is more misleading than helpful as a guide to policy because it oversimplifies and stereotypes what is in reality a continuum of business scales and structures. … Policy should concern itself with harmful practices, not with industry structure, and it should begin with a presumption of neutrality on issues of corporate size and market structure.”

The looming ‘Big Marijuana’ threat has become one of the last defensible arguments that prohibitionists rely on in their fight against cannabis law reform — these findings, however, may prove to dismantle that argument.

End


Jim McMahon Says NFL Players Should Have Access to MMJ

a word from our sponsors:

advertisement

advertise here

Jim McMahon, ex-NFL star quarterback who helped carry the Chicago Bears to victory in Superbowl XX, called for allowing NFL players to medicate using cannabis while speaking last week at The Cannabis World Congress & Business Exposition in Manhattan.

“There’s so many uses to this plant,” said McMahon. “Hundreds of thousands of people are dying from [painkillers] and there’s not one case of people dying from the hemp plant.”

McMahon is no stranger to cannabis advocacy, and has openly admitted to using the plant both during and after his illustrious football career — he’s even stated that he wishes he had used the plant more often as a safer and less-toxic painkiller option than the opiates that football players are typically prescribed by the fistful.

McMahon has said in the past that his marijuana use helped him kick an addiction that had the ex-football star taking up to 100 Percocets per month.

McMahon joins the Baltimore Raven’s ex-offensive tackle Eugene Monroe in his recent cannabis advocacy. In a widely-publicized move earlier this year, Monroe donated $80,000 to boost medical marijuana research. Monroe, who was the first active NFL player to advocate for medical cannabis, was cut from the Ravens last week and is now a free agent.

End


‘Tea-Party’ Congressman to Propose Legislation to Help Marijuana Researchers Access Drug

a word from our sponsors:

advertisement

advertise here

U.S. Representative Andy Harris (R-MD) is leading a coalition of lawmakers who plan to introduce legislation this week aimed at making it easier for prospective marijuana researchers to get Department of Justice approval to study the therapeutic benefits of the drug, the Baltimore Sun reports.

Under the plan, federal regulators would have two months to approve or deny research applications.

Harris was a vocal opponent against the district creating a taxed-and-regulated marijuana market in 2014, but the Johns Hopkins-trained anesthesiologist now says his “frustration” with legalizing medical cannabis is due to the lack of scientific research “about what it’s good for and what it’s not good for.” Harris attached language to a 2014 spending bill that prevented D.C. from regulating marijuana distribution despite its newly-legal status.

“I personally think it is the drug of choice in very, very few situations,” Harris said in the report. “Can it be useful in some situations? Probably. We haven’t really defined those very clearly.”

He noted that there is not “good data supporting widespread use,” however, part of the reason for the lack of data is researchers have a difficult time procuring the drug thanks to strict federal regulations and pushback from the Drug Enforcement Agency.

Harris is being challenged for his seat in the upcoming election by libertarians, who are pro marijuana, and they say his anti-pot stance is partly the reason they are stepping up to challenge him. According to a report from the Washingtonian, a January poll found Harris had about half the support of challenger Michael Smigiel (R) – 23 percent to 58 percent, respectively.

The measure is being supported by members of both parties, including Rep. Morgan Griffith (R-VA), Rep. Sam Farr (D-CA) and Earl Blumenauer (D-OR). A same-as bill is being proposed in the Senate by Sen. Orrin Hatch (R-UT), Sen. Thom Tillis (R-NC), Sen. Brian Schatz (D-HI) and Sen. Chris Coons (D-DE).    

End


Senate Committee Votes to Protect Banks Serving Legal Cannabis Companies

a word from our sponsors:

advertisement

advertise here

The U.S. Senate Appropriations Committee voted Thursday in support of expanding bank access to the cannabis industry.

The amendment, approved in a 16-14 vote, forbids any federal expenditures on the pursuit and punishment of banks for serving law-abiding companies in the legal cannabis space. The amendment is attached to the 2017 Financial Services and General Government Appropriations bill, which now heads to the Senate floor.

In a debate preceding the vote, the amendment’s sponsor Sen. Jeff Merkley (D-OR) argued that keeping cannabis companies from entering the national banking system is a threat to public safety.  “It makes no sense to have bags of cash, and it’s an invitation to organized crime, an invitation to theft, and invitation to tax evasion,” said Sen. Merkley.

“For the second year in a row, the Senate’s budget writers have voted to address the banking crisis facing our industry,” Aaron Smith, executive director of the National Cannabis Industry Association, said in a statement addressing the news. “Access to basic banking services is one of the most critical challenges facing legal cannabis businesses and the state agencies tasked with regulating them.”

“While an appropriations amendment isn’t a permanent fix to the banking problem, it is a significant step to correct a dangerous and unfair burden on responsible small-business owners and regulators,” Smith said.

End


Michigan Legalization Campaign Sues After Petition Signatures Ruled ‘Stale’

a word from our sponsors:

advertisement

advertise here

Marijuana advocates have sued the state of Michigan over a decision by the State Board of Canvassers to rule 137,000 signatures on their petition to get a legalization question on the November ballot invalid, according to a Detroit Free Press report.

The Board ruled the signatures were “stale,” meaning they were collected outside of the 180-day window available for petitioners to gather signatures.

The Board of Canvassers, Michigan Secretary of State Ruth Johnson, and State Elections Director Christopher Thomas are identified as defendants in the lawsuit.

Lansing attorney and MI Legalize Chairman Jeffrey Hank filed the lawsuit with Grosse Pointe Park lawyer Thomas LaVigne, claiming the group has “a litany of state and constitutional claims.”

“This isn’t just about marijuana,” Hank said in the report. “We’re trying to preserve the right of grassroots groups to get a question on the ballot.”

MI Legalize submitted more than 354,000 signatures to state officials, well over the 253,000 required for the initiative to appear on the ballot. With the Board voting 4-0 to invalidate 137,000 of those signatures, the group fell short – only about 217,000 signatures were considered valid.   

On June 8, just “minutes” after the board voted against the group, Republican Gov. Rick Snyder signed a law codifying the 180-day window.

“Establishing reasonable time limits on when signatures can be collected helps ensure the issues that make the ballot are the ones that matter most to Michiganders,” Snyder said in a release after signing the legislation.

The lawsuit, filed in Michigan’s Court of Claims, seeks “a minimum of at least four immediate rulings and one outcome – to place the MI Legalize proposal on the ballot of the next general election.”

The action also seeks monetary damages of $1.1 million plus punitive relief and other costs unless officials check the signatures against voter records, which MI Legalize asserts, will prove their validity.

End


Oregon Recalls Two Plant Cleaner Products Popular Among Cannabis Growers

a word from our sponsors:

advertisement

advertise here

According to an advisory issued June 16 by the Oregon Department of Agriculture, two popular plant cleaner products — Green Planet Nutrients Mega Wash and NPK Industries Mighty Wash — are being recalled following the discovery of an active pesticide ingredient that is not disclosed on their labels.

The state issued the following warning on Thursday:

The Oregon Department of Agriculture (ODA) has reason to believe the products Mighty Wash and Ultimate Wash, manufactured by NPK Industries, contain a pesticide active ingredient not listed on the label. ODA has tested both products and found it to contain the active ingredient pyrethrins. Use of Mighty Wash and Ultimate Wash could cause cannabis to fail Oregon Health Authority (OHA) pesticide testing requirements. Growers of all crops and retailers are advised to discontinue using or selling Mighty Wash and Ultimate Wash until further notice.

The Oregon Health Authority informed growers that although pyrethins pose low risk to humans unless exposed to very high concentrations, high levels of inhalation of the substance have caused respiratory irritation symptoms similar to asthma.

The Mega Wash formula is manufactured by Freq Water, Inc. of Central Point, OR for a Canadian company called H.I.T. Manufacturing, based out of Surrey, British Columbia. The Mighty Wash formula is manufactured by NPK Industries, located in Medford, OR.

End


The Marijuana Policy Project Endorses Libertarian Gary Johnson for President

a word from our sponsors:

advertisement

advertise here

The Marijuana Policy Project has formally endorsed the Libertarian Party candidate and former New Mexico Gov. Gary Johnson in his bid for the White House. Johnson served two terms as governor from 1995 to 2003 as a member of the Republican Party.

In a statement announcing their endorsement, MPP Executive Director Rob Kampia said Johnson “clearly has the best position on marijuana policy” out of the three candidates that will appear on the ballots in all 50 states, noting that the organization fights for “a single-issue” – regulating marijuana like alcohol.

“Legalization has been Johnson’s number-one issue for 17 years,” Kampia said in the statement. “MPP’s endorsement of Johnson was an easy call; the more difficult question is whether MPP should support a candidate who’s good on medical marijuana but bad on legalization, when the candidate is facing an opponent who’s bad on everything.”

Johnson received an “A-plus” grade in the group’s presidential candidate report card. Democrat Hillary Clinton, the party’s presumptive nominee received a “B,” while the Republican nominee, Donald Trump, was given a “C-plus.”

In January, Johnson stepped down from his role as CEO of Cannabis Sativa, a legal cannabis company, in order to focus on his campaign. In a recent interview with USA Today, Johnson indicated that he hasn’t used marijuana for “about seven weeks” and said he would abstain if he were elected.

The Libertarian Party elected former Massachusetts Gov. Bill Weld as Johnson’s running mate.

End


Microsoft Partners With Cannabis Tracking Software Company KIND Financial

a word from our sponsors:

advertisement

advertise here

Microsoft is the first major company to dabble in the flourishing cannabis industry following a partnership deal announced today with the Los Angeles-based seed-to-sale tracking software company KIND Financial, the New York Times reports.

Microsoft will be working with KIND’s “government solutions” division, which focuses on software for state and local governments in their pursuit of regulatory compliance. KIND’s Agrisoft Seed to Sale for Government software will be offered through Microsoft’s Azure Government, “the only cloud platform designed to meet government standards for the closely regulated cannabis compliance programs,” said Kimberly Nelson, Microsoft’s Executive Director of State and Local Government Solutions.

The tech giant’s willingness to cooperate with a company focused solely on legal cannabis could indicate that legitimate infrastructure is on its way for the nascent industry. “We do think there will be significant growth,” Nelson said. “As the industry is regulated, there will be more transactions, and we believe there will be more sophisticated requirements and tools down the road.”

David Dinenberg, Founder and CEO of KIND Financial, said in a company press release:

“No one can predict the future of cannabis legalization, however, it is clear that legalized cannabis will always be subject to strict oversight and regulations similar to alcohol and tobacco; and, KIND is proud to offer governments and regulatory agencies the tools and technology to monitor cannabis compliance. I am delighted that Microsoft supports KIND’s mission to build the backbone for cannabis compliance.”

The announcement follows another major development this week for Microsoft: the tech giant announced Monday that it was purchasing the social networking site LinkedIn in an historic $26.2 billion deal.

End


NFL Medical Marijuana Advocate Released by Baltimore Ravens

a word from our sponsors:

advertisement

advertise here

Eugene Monroe, an offensive tackle with the Baltimore Ravens, has been released by the organization, just months after advocating for medical marijuana therapy for NFL players, the New York Times reports.

Last month, Monroe donated $80,000 to Johns Hopkins University and the University of Pennsylvania for medical cannabis research.

“I can’t say for sure whether or not my stance on medical cannabis was the reason the Ravens released me,” Monroe said in the report. “However, as I’ve said in the past, they have distanced themselves from me and made it clear that they do not support my advocacy.”

Monroe was the first active player to call on the league to remove marijuana from its banned substances list and to fund medical marijuana research, especially as its potential use as a chronic traumatic encephalopathy (CTE) treatment.

“The NFL relies heavily on opioids to get players back on the field as soon as possible, but studies have shown medical marijuana to be a much better solution; it is safer, less addictive and can even reduce opioid dependence,” he wrote in an essay for the Players’ Tribune. “Some studies have also shown that cannabidiol (CBD) — one of the more than 100 cannabinoids found in marijuana — may function as a neuroprotectant, which means it can shield the cells in the brain from injury or degeneration. We need to learn more about this.”

In a statement released this morning, Monroe said, “Despite the current uncertainties, one thing is for sure: whatever happens in terms of my professional football career, I will never stop pushing for the League to accept medical cannabis as a viable option for pain management.”

According to the Times report, Monroe acknowledged he has had injury issues during his NFL tenure and ESPN indicated that the Ravens were in talks with the New York Giants to acquire the 29-year-old, but the deal never materialized.

Monroe was the eighth overall pick by the Jacksonville Jaguars in 2009 following a college career for Virginia during which he was a Unanimous All-Atlantic Coast Conference selection. He is now a free agent.

End


Major Medical Cannabis Brands Raided by California Police

a word from our sponsors:

advertisement

advertise here

Several prominent medical cannabis companies in California, including concentrate manufacturer Absolute Xtracts and CBD-rich products producer Care By Design, were raided by local law enforcement officers Wednesday morning — DEA agents were in attendance and supervising.

The raid targeted five company properties, all of which had been sharing a location under a cooperative agreement called the CBD Guild, formed together in 2014. According to Nick Caston, spokesman for Care By Design, the CBD Guild produces medicine “as determined by the voters in the 1990s, and we do it with the best practices of any company in the state.”

Law enforcement arrested Dennis Franklin Hunter, one of the organization’s founding members, under suspicion of using illegal and hazardous production methods in the chemical manufacturing of a controlled substance. Hunter — who spent four years evading police before he was caught in 2002 and handed a five year federal prison sentence for an illegal cannabis grow — had bail set at $5 million.

The CBD Guild laboratory is a 34,000-square-foot space in a Santa Rosa business park, on Circadian Way. The companies involved use highly pressurized carbon dioxide extraction devices to create artisan-quality cannabis concentrates. The guild’s focus is on CBD-rich products. According to Caston, together the companies serve dispensary locations in every major California city.

“This law enforcement action is unprecedented, unfortunate, and has the potential to deprive thousands of profoundly sick patients of much needed medicine,” Caston said. “We will cooperate fully with law enforcement in an effort to resolve this as quickly as possible, and hope to have our several dozen employees in Sonoma County back to work this week.”

Joe Rogoway, a Santa Rosa attorney representing the guild, said police had mischaracterized the cannabis companies. “They weren’t using butane, they use a process that includes CO2 which is a flame retardant; CO2 is what’s in fire extinguishers,” Rogoway said. “It’s not criminalized in California law.”

It’s possible, according to Rogoway, that the raids were a result of false claims made to law enforcement by a disgruntled former employee.

Care By Design is hosting a press conference and support rally today at 11:00 a.m. at the Sonoma County Superiour Courthouse in Santa Rosa to raise awareness about the overzealous enforcement act.

 

End


Grandma Cat Jeter: The Rise and Demise of Medical Cannabis in Washington

a word from our sponsors:

advertisement

advertise here

Cat Jeter is the founder of Deep Green, an award-winning full plant extracts manufacturer in Washington State. She recently joined our host Shango Los for a conversation about the history of the Washington State medical marijuana market, which will soon be absorbed by the recreational market due to pending regulations. In the interview, she discusses the movement that led to the creation of the medical cannabis market in Washington, how it grew and changed over time, and how the passage of I-502–Washington’s recreational cannabis ballot measure–affected the market and those who had dedicated their lives to serving patients. Listen to the interview using the media player below, or scroll down for the full transcript!

Subscribe to the Ganjapreneur podcast on iTunes, Stitcher, SoundCloud or Google Play.


Listen to the podcast:


Read the transcript:

Shango Los: Hi there, and welcome to the Ganjapreneur.com podcast. I’m your host, Shango Los. The Ganjapreneur.com podcast gives us an opportunity to speak directly to entrepreneurs, cannabis growers, product developers, and cannabis medicine researchers, all focused on making the most of cannabis normalization. As your host, I do my best to bring original cannabis industry ideas that will ignite your own entrepreneurial spark, and give you actionable information. To improve your business strategy, and improve your health, and the health of cannabis patients everywhere.

Today my guest is Cat Jeter. Grandma Cat Jeter is the founder of Deep Green, a full plant cannabis extracts producer located in Washington state. Founded with pediatric outreach as a core principle, award winning Deep Green has been a market leader in product testing, direct patient outreach, and branding from its very inception. I’ve asked Cat to be a guest on the show today because of her 43 years of medical cannabis experience. You know, every tribe has a keeper of the stories. Cat is a prominent protector of that flame in Washington. She has participated in nearly every aspect of the cannabis industry, and advocacy, and because of that, she has an understanding of the arc of cannabis history that very few people can offer.

During today’s show, we’re going to discuss the early days of medical cannabis in Washington, how the industry matured, and its very controversial demise coming on July 1st of this year. Welcome to the show, Cat.

Cat Jeter: Thank you so much, Shango, for having me. It’s a pleasure to talk to you and your listeners.

Shango Los: Cat, let’s start off at the beginning. Let’s go all the way back to 1998. You know, Initiative 692 was passed, which allowed medical marijuana in the state, and also gave permission to doctors to talk to their patients about marijuana. What was it like then? Were people caught off guard, and was there instantly an industry? What was it like in those very early days?

Cat Jeter: Well, I think it’s important to recognize that Washington has historically had a very tolerant attitude towards cannabis. We were busy culturally creating what you might refer to as a dankster class of citizen long before we ever got to any discussion of medical cannabis.

It goes back to our historical advocates in the mid-’90s. Joanne McKee, Ron Parker, Ralph Seeley, all of who were involved in legal action and led to a failed populous to action, I-685 in 1997. Then in 1998, a more streamlined 692 was ratified.

These are the very, very early years. This was still somewhat of a very frightening place. I think it’s important to recognize that Washington was still very, very decentralized in the way we approached medical cannabis. You needed to know someone. Or you needed to be working with the black market, essentially, to take care of your own personal medical needs, or needs for a friend. There was, to the best of my knowledge, only one operating co-op, and that was Joanne McKee’s and Ron Parker’s. The Green Cross over on Bainbridge Island.

Nonetheless, the desire was there. Yet it took a couple of more steps in the process to make that access readily available. Among them were, in 2007, Senate Bill 632, stipulated possession limits. Up until then, you could have cannabis, but how much? What was that trooper on the side of the road going to judge was how much. We didn’t have arrest protection. We had only affirmative defenses. You can see how that was a very uneasy intersection.

Then what really turned everything on it’s head was in 2010, when Senate Bill 5798 enabled more medical professionals to recommend cannabis. Now you had limits, suddenly you had the availability of getting that recommendation, so access had to follow. This is when we really see that the collectives, the dispensary model, really starts growing in Washington state.

Shango Los: Wow, that’s really interesting. The idea of early medical marijuana existing, but there not yet being a dispensary system to get it. That seems so messy. Where you know as a patient you are allowed to possess, but you’re still going to the black market for it. There must have been a lot of scrambling by patients who saw the promise of what medical marijuana might be able to do for them. Yet, how on earth do they get it?

Cat Jeter: Well, and this is, I think, true of almost any cultural movement. That the early adopters are out there and they’re scrambling, it can be risky. From my own family experience, my own father died during this period. We wanted to help him with his death process. I sent my son up to Northgate Mall to meet a fellow named Muadeeb, is all we knew him as. You know, we smoked joints, and we made butter for my terminally ill father. We weren’t even terribly well-versed in cannascience, nor in the process or production of particular products.

This is the same era that Rick Simpson was very busy reacquainting us with an ancient herbal extraction technique making concentrates using some type of a solvent. Yes, dark days, indeed, and confusing for people.

Shango Los: You know, those of us who are associated with cannabis mostly just in the last, say, five to ten years, RSO has always been there for us. Different solvents have always been there for us. What you’re talking about, it was very much the days of early pot brownies. Even though those have become iconic, for a lot of people, getting the cannabis out of the flower and into an edible was itself an advanced extraction technique.

Cat Jeter: Well, you know, I like to say this proliferation of medical cannabis over these last six years has brought about a radical shift in the way that we think of the plant. Not only of its various pieces, but the plant as a whole. You know, we’ve just had a renaissance of new products and reimaginings of cannabis and how we use it. Not only to heal, but to recreate.

Shango Los: You know, somebody who was in your position in those early days, I imagine there’s a lot of similarities to nowadays, where people are asking basic healthcare questions. How cannabis could help them. Nowadays, we’ve got the internet, and we’ve got conventions, and we’re able to exchange information. We’ve got the beginnings of new studies that are coming out of Europe. It must have been really challenging for you to have patients approaching you and asking for information and guidance, when the access to information was really hard.

Cat Jeter: Well, and it was even hard for me. You know, we knew that smoking a joint certainly made anyone who was going through chemotherapy feel a whole lot better, and help them to keep their next meal down. We didn’t have any real sense, I don’t think, even as a culture in exactly how, what we refer to now as cannabinoid therapy, at various dosing levels from low to high, how that type of approach might help us. The shift has just been radical in the last ten years.

Shango Los: It must have been really strange, too, to be legitimized with the passing of the Initiative to allow medical cannabis, and yet still having to go the black market. That shifty vibe that you can, you know, sometimes feel when you’re involved in a prohibited activity. Yet, you’re doing it for the most right and allowable reasons. The mixture of the prohibition culture and medical marijuana culture must have felt very awkward.

Cat Jeter: Well you know, I think this is really one of the inhibiting factors on growth of medical cannabis right now. We refer to it as legal, yet there is a tremendous amount of oppression still associated with medical cannabis. Your job can be held hostage to this. Your family might be held hostage to this. Although we see much less of it in Washington nowadays. You know, there’s still a tremendous amount of judgement associated with outing yourself as someone who chooses a safe herb over a pharma solution.

We’re making progress, but we certainly haven’t pulled the veil back yet. The discomfort is not yet alleviated.

Shango Los: You know, you mentioned the explosion in medical marijuana once the dispensaries existed. Certainly after the dispensaries existed, there was a lot more access. There were more people being able to make money by providing medicine as well. Was anybody really making money ahead of the dispensaries coming into existence? It sounds to me like there were, it probably just infused a bunch of new customers into the black market that had affirmative defense. There probably wasn’t enough economic viability of that model to really have anybody making much money before the dispensaries.

Cat Jeter: I think that’s right. This is one of the ways in which our early medical states are really rather unique, when comparing them against the more commercial models that have come along recently. That is, we do come from a place of compassion. You know, you got to be compassionate when you’re risking yourself in a very, very limitedly defined legal world to help your brother, or your sister, or your mother, or your child.

Now, we are approaching it in a much more broad based approach, and a much more commercial approach. Which, of course, is going to lead to a more normalization of the commercial model. I really didn’t see a lot of money flowing through the system until we got to a point where there were a lot of collectives beginning to appear. Then there would be a few that were just killing it on the commercial level. Naturally they were doing very well financially. This is simple economics. With risk comes reward. It has been very risky throughout all of our medical phase here in Washington.

Shango Los: Well, we’re gonna talk a little bit more about the risks involved, and what enforcement looked like during medical marijuana in Washington after our break. We are going to take that first break right now. You are listening to the Ganjapreneur.com podcast.

Because you listen to the Ganjapreneur podcast, it is very likely that you are a business owner now, or that you plan on getting into cannabis soon. If you’re starting a business, at some point you’re gonna want some swag with your name on it to give away, or maybe even to sell. Promotional items are a way to stay in your customers’ life long after come into contact with them. It reminds them to double back and buy more of your stuff, but it also reminds them to tell their friends about you.

Well, at Ganjapreneur, we’ve been asked by so many new cannabis business owners for referrals on promotional items because they’re getting ready for a convention or a party, or that they just want to give it away.  So we went ahead and brought together some preferred vendors, and put them on our website for you.

The web address is ganjapreneur.com/promoitems. Everybody loves doing lighters and t-shirts, and those are still huge winners, of course. Some folks are even now doing logo-ed silicone dab jars and rig-rags, too. There so much to choose from. The website is ganjapreneur.com/promoitems. Go get some cool stuff to promote your company.

As a cannabis entrepreneur, you know how challenging recruiting quality talent can be. Your day’s already busy enough, and yet there’s an ever growing pile of resumes on your desk, and your team is begging you to hire more help. Hiring the right person can make a profound impact on your company. There’s no reason that you have to suddenly have to be an expert hiring manager. Not when there’s Viridian Staffing.

Viridian Staffing recruits solely for adult use cannabis, medical marijuana, and hemp companies, and those that service them. Viridian Staffing’s recruiters each have over ten years of experience, and they will use that experience to recruit the kind of employees that will make you look good. Whether you’re looking for a master grower, extractor, grow room support, or trimming, Viridian can find an appropriate person in your area. They can even recruit administrative or graphic design professionals who may not need cannabis experience.

Because you are a start-up, you may also need human resources help for a while. Viridian Staffing can make sure that your HR files are complete, and keep you out of trouble with state and federal employment requirements.

Because the cannabis industry is booming, cannabis recruiting companies are popping up all over the country. Good marketing does not mean good recruiting. Some of the recruiting shops that have opened are run by novices who do not yet have a thorough understanding of employment law, and the complexities of hiring for cannabis. Don’t hire an amateur to find you a professional. Consider Viridian Staffing to make that stack of resumes disappear, and complete your team with exactly the hire you were hoping for.

You can find out more at viridianstaffing.com. That’s V-I-R-I-D-I-A-N-staffing.com. Now, back to the show.

Welcome back. You are listening to the Ganjapreneur.com podcast. I’m your host, Shango Los. Our guest this week is cannabis patient advocate and entrepreneur, Cat Jeter.

Cat, before the break we were talking about how in the early days, patients had to go to the black market because this was ahead of the dispensary system. That kind of makes me think that it may have been common for patients to get busted by the police, because they’re going about what could seem like a black market transaction … But as a patient, they’re actually allowed to have the cannabis. How many people were getting busted back in the day?

Cat Jeter: Well, I think there were, you know, especially when that intersection between black market and what was medical was being defined, I think it was business as usual the way we had seen it. Now, we’ve mentioned that Washington was a tolerant state, but certainly if you were pulled over on the side of the road, and any reason given to crack your trunk and had a half a pound back there. Whether you were getting ready to bag it out, or you were getting ready to make full plant extract, I don’t think law enforcement particularly cared.

That transferred into a very focused effort as collectives began organizing and serving with the demand for access and product in Washington. It seemed to be, you know, there were a lot of variables. One was geographical. You certainly wanted to be in a friendly county, or a friendly city. A lot of it was the profile with which you carried yourself. You know, were you driving a new Ferrari, or you know, showing it off?

Again, we talked about with risk comes reward, but in an age of judgment, that might not have been your best stance for safety. What we saw were clusters of busts. Where Westnet Drug Task Force would sweep down on two or three organizations at once, and create a real climate of fear. You never saw a whole industry who could drop its umbrellas and be on the road any faster than the medical cannabis industry when there were busts happening.

It made it really very tenuous. Slowly, we figured out where the safe jurisdictions were. I think the best players in the industry figured out they needed to get a business license, communicate with their communities, and take a best practices approach. It still didn’t stop the fact that this is still federally illegal, and you operated by the forbearance of your local authorities.

Shango Los: You know, before the break we were talking about how in the early days, it was mostly all folks could do to extract cannabis out into a fat, like butter, and make it into an edible for patients who were prepared to be smoking, and yet still needed the cannabinoids inside them. It was interesting to me to consider that over your 43 years of experience, you’re probably answering a lot of the same questions that patients were asking then, now. I wonder to what degree your answers have changed. Obviously, we’ve learned so much more as a cannabis scene than we knew 43 years ago.

Cat Jeter: A lot of the questions are the same. Simply because there are so many people who are uneducated, under educated, or misunderstand. A lot of the questions are evolving, too. Certainly the questions where someone is terminally ill, and fighting for that last bit of quality of life that they may have, those questions have stayed the same. Our understanding of cannabis as a helpful healing agent at that point has not radically changed over the last 20 years. These were the examples that we used to legitimize medical cannabis, and get it legalized to begin with.

More recently, we’re seeing questions about how cannabis can help with addiction issues, or persistent pain, or depression. How you can access cannabis that doesn’t make you high, for instance. We hear more questions about accessing cannabis for on-going health, rather than end of life issues. I think all in all, it demonstrates a cultural competence and evolving awareness of the power of the plant.

Shango Los: Yeah, that makes a lot of sense. I would think that people’s questions are getting more sophisticated themselves. In the early days, they were just hearing a whisper over a dinner table, or something. Or you know, a recommendation from a friend. Whereas now, people will have heard that, they will have Googled a little bit, and then they’re coming for more of an expert opinion, built on top of that. I would think that the people who approach you are approaching with much more sophisticated questions, generally.

Cat Jeter: Without a doubt. Thank heavens for the information age. We have better access now to that growing body of science. We’re able to network better with each other. We understand conditions that are helped with cannabis. We understand how various components of the plant, from cannabinoids, to terpenes, to to flavanoids, to even the waxes and lipids. How they help the healing process, and help the plant to work in whole.

Certainly one of the biggest discussions lately has been the entourage effect, instead of just focusing on THC or CBD. We’re beginning to look at how the various constituents of the plant interact to make it an even more powerful healing agent. We’ve also seen that the discussion has shifted from cure exclusively to focusing on quality of life instead.

Shango Los: You know, as far as the quality of life goes, at the top of the show you were talking about how in 2010 the scene kind of got more protections, and a little bit more of a green light as more healthcare providers were allowed to write prescriptions. Also there were more protections because they started to give the carry amounts, and how much you can have on your person, and have at home.

From what I saw, this was turned up even more in February of 2014 when the Cole 2.0 Memo came out. They gave the necessary aspects for individual states to do medical marijuana. At the time, Washington seemed to be in a good position on all of those. It really caused the market in Washington to explode. The number of dispensaries went up. People really felt like they had protections at that point, that before that were simply not as significant. Were people looking for the Cole 2.0 Memo to happen? Or were they just really pleasantly surprised when it came out?

Cat Jeter: You know, I think the Cole 2.0 Memo is one of those situations where I ask myself was it really medical driving it along, or do we need to also acknowledge the fact the two states had just said we’re over your prohibition. We’re going to legalize for all 21 plus adults. I found that it had less to do with medical from my own point of view. A fair amount of it, for medical, felt like I see your lips moving, but what have you done for me lately.

Shango Los: Yeah.

Cat Jeter: You know, in Washington we were right in the middle of a very aggressive persecution of the Kettle Falls Five, out in the eastern side of the state. This at a time when the DOJ, Department of Justice, had been told quit spending funds on this. We were, I think, looking for more positivity, as opposed to another list of prohibitions. Nonetheless, there’s no doubt that it did cause the absolute explosion, it in addition to the 502 passage, in anticipation of what was going to be a legal market. It’s been a wildly successful little petri dish of … For 30 years I’d been siting back and wondering what if cannabis was legal? Well you know what, coming at a time when our own economics had been a downturn, it was Washington’s own economic stimulus plan. There were new firms. There were people with new jobs.

However, I have to comment, too. Our wild embrace of the cannabis lifestyle, including High Times events, and local cannabis competitions, absolutely may have been our downfall at a time when the rest of the community was not moving as fast in their understanding of safe recreation with cannabis, and safe healing.

Shango Los: Yeah, I think that you nailed that on the head, Cat. The scene as a whole exploded, and that meant you had more people doing compassionate care, and also more people seeing a financial opportunity, and also more people seeing an opportunity to party in the open a little bit more. All the different aspects of medical cannabis all got bigger at the same time. There were plenty of opportunities for people to point at minor parts of the community and say see, that’s what we think is bad, and that’s what medical is. Actually, whatever part of that was either being misinterpreted by the general public who don’t understand the medical cannabis scene as a whole, or simply it was a very insignificant part of the scene that they really wanted to shine their light on.

You know, similarly, you were talking about the economic development that came with it. Where I live out here on Vashon Island, after the Cole 2.0 Memo, businesses really got serious about supplying the dispensaries all through Washington state. We’ve been growing high quality indicas here on Vashon Island since the ’70s. You know, the fact that people grow was not a big deal here. The idea that suddenly those folks were able to come out of the closet, get business licenses, develop relationship with dispensaries, start delivering their product, getting it off the island. Actually, starting to help develop, you know, have real economic development. Families that were once fringe, being able to start to participate in true economics state-wide. That was a really beautiful thing. That created a wonderful opportunity.

At the same time, though, people were really aware that 502 had made the ballot, and had passed. We all felt a transition starting to happen. That transition was starting to scare many people. Oh, looks like it’s time for us to take another break. Let’s take a quick break, and we’ll come back and talk about medical marijuana after I-502 passed. You are listening to the Ganjapreneur.com podcast.

The Ganjapreneur podcast is listened to by tens of thousands of cannabis entrepreneurs and enthusiasts every single week. These folks are most likely your target customers, and we’d like to introduce you to each other. Our down to earth and information rich commercial breaks can deliver your message to the cannabis business community, and others who just find relief in getting high.

If you want to reach out and connect with our audience in the most personal way that we can offer, go ahead and drop us an email at grow@ganjapreneur.com, and we can talk about you becoming a commercial sponsor of the podcast. Thank you for listening and being part of the Ganjapreneur family. Now back to the show.

Welcome back. You are listening to the Ganjapreneur.com podcast. I am your host, Shango Los. Our guest this week is cannabis patient advocate and entrepreneur, Cat Jeter.

Before the break, we were talking about the transition that everybody felt coming when I-502 recreational marijuana made the ballot, and passed with a real significant support in the state of Washington.

It created this split in the medical marijuana scene, as more people started moving their intentions toward getting commercial licenses, moving over to the recreational side with the eyes of expanding their businesses and hopefully making some money. Then other folks who maybe didn’t have as much access to capital, and maybe were more patient-centric. For whatever anybody’s personal reasons were, the scene absolutely started to split. Did you see that, too, from where you were sitting, Cat?

Cat Jeter: Oh, without a doubt. It was an extremely, and still is, contentious age. I’ve seen former allies break apart and become each other’s worst enemy over this issue. You know, really at issue is how resistant are you going to be to change?

You know, at the end of the day, if everyone who’s negotiating for change goes away a little bit unhappy, you know you’ve probably got a workable deal. Unfortunately, in creating rights for adult users, we had to step … Or didn’t maybe have to … But the rights of medical cannabis patients were disregarded. A number of other aspects were rather negative about the bill, too, in just indicating an understanding of cannabis. The per se DUI basically made every medical patient a de facto altered driver. Yet there’s no scientific evidence that supports that five nanograms of cannabinoids in your blood stream somehow impair your driving.

You know, the whole idea was sold after an initiative was run in the previous year, which we always felt like plowed the ground for legalization. It was run by and large by the Heritage Medical and Heritage providers. We felt like we’d reaped a corrupt harvest based on our plowing efforts in the year before.

Nonetheless, don’t we have to accept and celebrate the fact that my grandkids, who are quickly approaching 21, will no longer be looking at jail time for simple possession. Society moves back and forth. You’re always swinging to one side or the other of the middle. Truth lies in that negotiation of culture and activity, right.

Shango Los: Yeah.

Cat Jeter: You know, it has been difficult. Along the way, we should have known that it would never last. We’d been working from the compassionate model, and very few people taxing their products, or declaring taxes on their products. We find ourselves now in a model, even with the compressed tax column, that patients are going to be … Unless they give away their HIPAA medical rights with the registry … Paying sales tax on the only medicine in the state of Washington. They have a right to feel oppressed.

I think the folks who worked from the compassionate point of view have every right to feel that in an age of disinformation, leading up to the licensing, and what we now think, suspect, maybe even have some evidence, could have been some favoritism in the granting of licenses for what goes forth next.

I think we also have a right to feel that as pioneers, our intellectual and our financial capital has been squandered in this state. We’ve put the leaders on the outside looking in, and the newcomers on the inside laughing.

Shango Los: Yeah, that’s a really good point. You know, that’s not how the other states did it. You know, in Colorado, they took their existing medical marijuana structure, and blessed it, and then helped it transition to become what was then a combined recreational and medical. Whereas in Washington, they did their best to sideline and exclude everybody who was involved in medical, and then bring in all new people from other industries, and gave them the licenses to produce cannabis.

You know, I knew that this was going to get ugly back at that very first WSLCB meeting downtown, with that packed room. You know, sitting down in the chairs were patients, and a lot of new business faces that I had never seen before. Then in the back of the room were a bunch of really angry activists with signs. They were interrupting the folks who were speaking. For them, this was the end of patient access. They saw the mess that was coming down the line. So many of us were really hoping that they were overreacting.

Now, you know, two years later, we see that they nailed it. Their anger was justified. They were just prescient in understanding what was going to happen two years earlier than everybody else. That was such a clear manifestation of the schism that was coming with the passing of I-502, and then 5052 last year, which got rid of all the dispensaries.

Here we are today, right. It’s June 7th, and we’ve got 23 days until the July 1st deadline when all the dispensaries have to be closed and the, whatever, 19 years of medical marijuana as we know it comes to an end. What do you see as the landscape for medical marijuana going forward, Cat? I mean, is it even worth calling medical marijuana anymore? What do you see as the future?

Cat Jeter: Well, you know, I think there’s a case that can be made that all cannabis is medical, right. You know, if it’s true that it’s good for your he5alth, then even casually toking up a joint can be somewhat medical for you. You know, those people weren’t wrong. While I think maybe we could have espoused a little softer shoe approach, and in fighting for our rights, the worst has in fact come to happen.

Patients are in a panic. No doubt about it. At our office, we get many calls a day. Where am I going to be able to find Deep Green in the future? We tell them we’re scrambling like all the other historical medicals as fast as we can to get there for you. A current survey of the 502 shops shows no medical products in them right now. Or a very, very, very limited selection.

Now, is that … You know, it’s a chicken or egg situation currently. You can’t talk about medical in a 502 retail environment. Is it they can’t talk about it, so why would they have it. Or is it they simply don’t want it. What I hear from the 502 rec store owners, it’s all about the THC and the recreational aspect of it.

You know, many access points have closed already, further constricting access in these final months for our patients. A few are committed to serving the public right up until the end, including at least one that I know of. That’s going to have their doors open right up until midnight on June 30th. I understand at least two farmer’s markets are going to fight for their ground, and try to create a new private model. In which, as a member, you can still access the Heritage and Legacy farmers that have served the market so well up until now.

Many medical brands, my own included, we are busy scrambling in negotiations with companies that already have processing capacity. Looking either for space to process our own product, or branding situations. You know, a majority of the historical cottage brands are simply going to go by the wayside, or going to slide back to what could be called the black market again.

I reject that term, and I prefer to call it now that people’s market. The people have ratified their desire for cannabis. Not one, not two, but three different times now in the state of Washington. How many times do we have to ask, how times do we have to demonstrate to our legislators that this is what we want. You need to find a viable framework for it.

Shango Los: You know, the examples that you give of the people who are presently in the medical market transitioning, those were all more or less legal venues. I like what you say about the people’s market. Which some will call the casual market, or the informal market. It seems to me that we should expect to see a blossoming of the informal market because we’re in a different situation than we were ten years ago.

It’s not that there is a black market of loosely associated people. These are people who have been working together the last five to ten years. We’ve got solid networks. People know who each other are. People are giving each other their business cards. I find it very difficult to believe that the sate is going to be as successful as they hope in eradicating the unlicensed and untaxed medical artisan craftspeople from making the medicine that they not only use to pay their bills, but has become people’s passion and moral drive to help patients.

Cat Jeter: I could not agree any less with that. First off, let’s start with just the definition. We talk about these as black market, or the state casts us black market … But how black is it? When it’s your neighbor three doors down, you’ve known him for 15 years. You know, he just put his daughter through college with the few pounds of artisan cannabis that he creates in her old bedroom.

You know, these are new economic days, in which we are all feeling more and more economically disenfranchised at a country, or even state-wide level, and feeling more empowered to look within our closer communities to serve our own needs. We see this with local food. We see this with local artisan crafts. We’re seeing it with local artisan cannabis.

You know, the power has tried to eradicate us for 80 years now. I like to ask our legislators how are you doing so far? You know, I sense that we are winning this battle for health and for minds. You know, there are difficult times coming ahead. I don’t doubt that there are going to be a few significant enforcement actions designed to scare us again.

Again, I think we’re winning this debate. I think it is a debate. We’ve swung the pendulum over to the right again. Skills are not going to simply to be allowed to lie fallow. The market will demand them. It’s a shame that many of these business owners will be transformed into high level talent for extraction companies, perhaps, or as master growers. We’re better off when we have small business, but there’s little appetite on the part of the state right now for that decentralized small cottage industry.

Shango Los: Yeah, that’s very true. Cat, one more thing I want to ask you before we wrap up, since we’re coming to the end of the show. You know, we’ve got people who listen to our show, tens of thousands of people all across the country, and even internationally. Most of those locales are either just now adopting medical marijuana, or they have and they are moving towards recreational. Most everybody’s got some kind of medical marijuana in play, even if it’s being presented in front of the legislature and getting beaten right now.

With the scope of your 43 years of experience, what message can you send out to medical marijuana activists in their individual locales that can help buoy them that they’re on the right path?

Cat Jeter: I think I could say be calm. First off, not everything happens in a day. Not everyone will learn what you have learned in a day. You will take a beating one day, and come back victorious the next. Stay calm in what you ask for. Don’t expect everything, and don’t take everything as a defeat, when in fact you have a win on your hands. In terms of progressing the conversation forward.

Most of all, continue to love your community. Not everyone will stand in the exact same space that you do with respect to cannabis. If we start assassinating each other in a circular firing squad, who’s going to be there at the end? Our desire to free the plant will fail, and it will be a turnover to big pharma and corporate farming interest. That’s not what we want. We see this as a populous issue. If we can all just ratchet the level of anxiety, and remember that we come from different places, and that we agree on 97% of everything, just differ on 3%. Let’s not kill each other over that 3%. Let’s keep marching this forward.

Shango Los: Very well said. Cat, thank you so much. Not only just for being on this show, but for your decades of service to the scene, cannabis education, and sharing your passion and mentorship with the rest of us.

Cat Jeter: It is my pleasure. Thank you for having me on, Shango. Good luck to everyone who’s listening, and who is still fighting this fight right along with Washington.

Shango Los: Grandma Cat Jeter is founder of Deep Green. You can follow Cat Jeter and Deep Green extracts on their Facebook pages. You can also go to the DeepGreenExtracts.com website for more information on that specific company.

You can find more episodes of the Ganjapreneur podcast in the podcast section at Ganjapreneur.com, and in the Apple iTunes store. On the Ganjapreneur.com website, you will find the latest cannabis news, product reviews, and cannabis jobs updated daily, along with transcriptions of this podcast. You can also download the Ganjapreneur.com app in iTunes and Google Play. For info on me and where I will be speaking, you can go to ShangoLos.com.

Do you have a company that wants to reach our national audience of cannabis enthusiasts? Email grow@ganjapreneur.com to find out how.

Today’s show was produced by Michael Rowe. I am your host, Shango Los.

End


Inaugural Imperious Expo Coming to Tacoma on July 20-21

a word from our sponsors:

advertisement

advertise here

The inaugural Imperious Expo, a marijuana business conference dedicated to spotlighting the medical and industrial cannabis industries, is coming to the Tacoma Dome Exhibition Hall in Tacoma, Washington this July 20-21.

Boasting dozens of highly qualified speakers, the event’s topics will range from cannabis cultivation, diversity, insurance, legal issues, business licensing, to sustainability and more. Speakers at the conference have been drawn from industry experts everywhere, and will include a presentation by legendary cannabis activist Ed Rosenthal — Eric Brandstad of Forever Flowering Greenhouses will make the event’s keynote address.

Other speakers include David Muret of Viridian Staffing, Chris Beals of Weedmaps, Aaron Pelley of Pelley Law, Aaron Pitsicalis of Purple Haze Properties, and dozens more. Ganjapreneur‘s own podcast host and brand strategist Shango Los will also be speaking.

The Imperious Expo is a primarily business oriented conference, with an emphasis on business to business (B2B) strategies and networking opportunities for medical and industrial marijuana enterprises. According to event co-founder and managing partner Eric Norton, the Imperious Expo was designed from its start to be “a medical and industrial hemp model [trade show] that will fit into any state as it goes green.”

“It’s obvious that many other trade shows got into the industry for quick money,” Norton said in a phone interview. “That’s not the case with us: having a medical model in Washington — because it’s full-blown rec — has cost us money. We would be able to throw a bigger [recreational] show… but that’s not our focus. And that’s enabled us to draw in speakers from all over the country.”

The Imperious Expo will be an annual event, held in the Tacoma Dome itself in future years. Norton said there are plans to bring the show to Phoenix, Arizona and Portland, Oregon — though dates for future shows have not been announced.

Tickets are available online. General admission tickets for the entire event cost $149, one day passes are available for $99. Both passes grant full access to the exhibition hall and that day’s speaker lineup.

End


Survey of New York Patients and Caregivers Finds Serious Flaws in Medical Marijuana Program

a word from our sponsors:

advertisement

advertise here

A recent survey by the Drug Policy Alliance found New York’s medical cannabis program is plagued by unaffordable medicine and “overall inaccessibility,” based on feedback from 255 patients and caregivers.

According to the report, more than half of those surveyed have, so far, been unsuccessful finding a doctor to certify them for the program and three out of five have been waiting three to four months to find a physician registered with the program. Of the respondents who have obtained medical cannabis through the program, 77 percent reported being unable to afford the necessary medicine, with 70 percent saying it would cost them $300 or more per month.

“New Yorkers deserve more transparency and information about how the state’s medical marijuana program is performing,” Julie Netherland, PhD, director of the Drug Policy Alliance’s Office of Academic Engagement said in a press release. “Our data confirms what we have heard from patients and caregivers for months – New York’s program is not easily accessible, and even for patients who manage access the program, most cannot afford the medication. We urge the legislature to act quickly and pass these bills to improve the program so patients in need can get relief.”

Following their report, the group is urging lawmakers to pass three bills that would help overhaul the system. The bills, sponsored in the state Assembly by Assemblyman Richard Gottfried (D), would authorize nurse practitioners and physician assistants to certify patients for the program (A.9510), add chronic pain as a qualifying condition (A.9514A), and add more producers and dispensaries in the state (A.9747A). Both carry same-as bills in the Republican-dominated state Senate. A.9510 (S.6998) passed the Assembly last month and now sits in the Senate Health Committee, where it is sponsored by Sen. Diane Savino (D). A.9514A and A.9747A have both stalled in the Assembly following their move out of their Health Committee.

The lack of dispensaries allowed under the law was a concern for advocates from the beginning – allowing for just 20 total dispensaries for a state of almost 20 million people and 54,000-square-miles. The Drug Policy Alliance survey found that 27 percent of registered patients and caregivers travelled one to five hours to access a dispensary.

During a press conference last week, Gottfried and advocates lobbied for lawmakers to pass the proposals. During his remarks, Gottfried was hopeful the bills would be voted on by lawmakers this session – which ends on June 16.

End